section name header

Pronunciation

tem-AZ-a-pam

Classifications

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: benzodiazepines

Indications

BEERS REMS


Action

  • Acts at many levels in the CNS, producing generalized depression.
  • Effects may be mediated by GABA, an inhibitory neurotransmitter.
Therapeutic effects:
  • Relief of insomnia.

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed; crosses blood-brain barrier. Probably crosses the placenta and enters breast milk. Accumulation of drug occurs with chronic dosing.

Protein Binding: 96%.

Metabolism/Excretion: Metabolized by the liver.

Half-Life: 10–20 hr.

Time/Action Profile

(sedation)

ROUTEONSETPEAKDURATION
PO30 min2–3 hr6–8 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash

EENT: blurred vision

GI: constipation, diarrhea, nausea, vomiting

Neuro: hangover, abnormal thinking, behavior changes, dizziness, drowsiness, hallucinations, lethargy, paradoxic excitation, sleep driving

Misc: physical dependence, psychological dependence

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Restoril

Contr. Subst. Schedule

Schedule IV (C-IV)